Blog

Naveen Pemmaraju: I was honored to Co-Chair the Inaugural in-person MPNCo and D Meeting October 2023 with Prof Ruben Mesa, MD and Prof Claire Harrison this week in Paris, France

Photo from Naveen Pemmaraju/LinkedIn

Oct 11, 2023, 19:22

Naveen Pemmaraju: I was honored to Co-Chair the Inaugural in-person MPNCo and D Meeting October 2023 with Prof Ruben Mesa, MD and Prof Claire Harrison this week in Paris, France

Naveen Pemmaraju shared on LinkedIn:

“I was honored to Co-Chair the Inaugural in-person MPNCo&D Meeting October 2023 with Prof Ruben Mesa, MD and Prof Claire Harrison this week in Paris, France, as part of the The Joint Meeting of the International Academy for Clinical Hematology (IACH) overall led by Prof Mohamad Mohty | Thanks to all of our MPN & Leukemia friends & colleagues who joined us this week from all over the world – the meeting was a giant success due to so much participation from the international MPNSM community & we are already looking forward to next year together !!”

Naveen Pemmaraju holds multiple positions at the University of Texas MD Anderson Cancer Center,including Executive Director of Cancer Medicine, the Director of the Leukemia – Cancer Network, and Professor in the Department of Leukemia. He is also the Director of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) program at the MDACC Leukemia Department. Dr. Pemmaraju’s clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), myeloproliferative neoplasms (MPN) and acute myeloid Leukemia (AML). Dr. Pemmaraju is also a well-known social media influencer.

Source: Naveen Pemmaraju/LinkedIn

Naveen Pemmaraju holds multiple positions at the University of Texas MD Anderson Cancer Center, including Executive Director of Cancer Medicine, the Director of the Leukemia – Cancer Network, and Professor in the Department of Leukemia. He is also the Director of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) program at the MDACC Leukemia Department. Dr. Pemmaraju’s clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), myeloproliferative neoplasms (MPN) and acute myeloid Leukemia (AML). Dr. Pemmaraju is also a well-known social media influencer.